Abstract
Coxiella burnetiiis the bacterial causative agent of the zoonosis Q fever. The current human Q fever vaccine, Q-VAX®, is a fixed, whole cell vaccine (WCV) licensed solely for use in Australia.C. burnetiiWCV administration is associated with a dermal hypersensitivity reaction in people with pre-existing immunity toC. burnetii, limiting wider use. Consequently, a less reactogenic vaccine is needed. Here, we investigated contributions of theC. burnetiiDot/Icm type IVB secretion system (T4BSS) and lipopolysaccharide (LPS) in protection and reactogenicity of fixed WCVs. A 32.5 kb region containing 23dot/icmgenes was deleted in the virulent Nine Mile phase I (NMI) strain and the resulting mutant was evaluated in guinea pig models ofC. burnetiiinfection, vaccination-challenge, and post-vaccination hypersensitivity. The NMI ∆dot/icmstrain was avirulent, protective as a WCV against a robustC. burnetiichallenge, and displayed potentially altered reactogenicity compared to NMI. Nine Mile phase II (NMII) strains ofC. burnetiithat produce rough LPS, were similarly tested. NMI was significantly more protective than NMII as a WCV; however, both vaccines exhibited similar reactogenicity. Collectively, our results indicate that, like phase I LPS, the T4BSS is required for full virulence byC. burnetii. Conversely, unlike phase I LPS, the T4BSS is not required for vaccine-induced protection. LPS length does not appear to contribute to reactogenicity while the T4BSS may contribute to this response. NMI ∆dot/icmrepresents an avirulent phase I strain with full vaccine efficacy, illustrating the potential of genetically modifiedC. burnetiias improved WCVs.

This publication has 79 references indexed in Scilit: